Skip to main content

Table 2 Seroconversion and seroprotection rates 4 weeks after seasonal influenza vaccination in patients with COPD

From: Seasonal influenza vaccination in patients with COPD: a systematic literature review

Reference Country Influenza season Vaccine type Influenza type/subtype Immunogenicity outcome
  Percentage with ≥4-fold increase of antibody titres (95% CI) (n/N) Percentage with antibody titre ≥1:40 (95% CI) (n/N)
Nath et al., 2014 [34] Australia 2010a TIV Type A/H1N1 43% (9.9–81.6) (3/7) 100% (83.2–100) (20/20)
Chuaychoo et al., 2010 [31] Thailand 2006–2007 TIV All subjects   
 Type A/H1N1 80.0% (69.6–87.5) (60/75) 93.3% (85.1–97.1) (70/75)
 Type A/H3N2 84.0% (74.1–90.6) (63/75) 88.0% (78.7–93.6) (66/75)
 Type B 61.3% (50.0–71.5) (46/75) 72.0% (61.0–80.9) (54/75)
Subjects > 60 year   
 Type A/H1N1 79.7% (68.8–87.5) (55/69) 94.2% (86.0–97.7) (65/69)
 Type A/H3N2 84.1% (73.7–90.9) (58/69) 88.4% (78.8–94.0) (61/69)
 Type B 59.4% (47.6–70.2) (41/69) 71.0% (59.4–80.4) (49/69)
Gorse et al., 2004 [32] US 1998–1999 TIV + placebo  Type A/H1N1 59.4% (40.6–76.3) (19/32) -
 Type A/H3N2 53.1% (34.7–70.9) (17/32) -
 Type B 34.4% (18.6–53.2) (11/32) -
Wongsurakiat et al., 2004 [35] Thailand 1997–1998 TIV (2 doses)b  Type A/H1N1 80.0% (67.7–89.2) (48/60)‡ 76.6% (64.0–86.6) (46/60)
 Type A/H3N2 76.7% (64.0–86.6) (46/60)‡ 86.7% (75.4–94.1) (52/60)
 Type B 50.0% (36.8–63.2) (30/60)‡ 45.0% (32.1–58.4) (27/60)
Gorse et al., 1997 [33] US 1994–1995 TIV + placebo  Type A/H1N1 46.2% (19.2–74.9) (6/13) -
 Type A/H3N2 61.5% (31.6–86.1) (8/13) -
  1. CAIV-T cold-adapted influenza virus, CAV cold-adapted influenza virus, n number of subjects, RCT Randomised controlled trial, TIV trivalent influenza vaccine, US United States, n/N number of subjects with a response/HI titre ≥ 1:40 over the total number of subjects, 95% CI 95% confidence intervals. Exact 95% CI calculated when not provided in the article
  2. aStudy conducted in Australia: influenza season from April 2010 to November 2010
  3. bResults after dose 1 are shown. 4-fold increases after the second dose were low
  4. -not reported
\